819800-93-6

Basic information

• Product Name: tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate;1-Boc-4-hydroxy-4-(nitroMethyl)piperidine;4-hydroxy-4-(nitromethyl)-1-Piperidine carboxylic acid 1,1-dimethylethyl ester
• CAS NO: 819800-93-6
• Molecular Formula: C11H20N2O5
• Molecular Weight: 260
• Mol File: 819800-93-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate(819800-93-6)
• EPA Substance Registry System: tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate(819800-93-6)

Safety Data

• Hazardous Substances Data: 819800-93-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate is used as a synthetic intermediate for the preparation of various organic compounds. Its unique structure and functional groups make it a valuable building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate is used as a key component in the development of new drugs. Its reactivity and stability can be leveraged to create novel therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Chemical Research:
Tert-butyl 4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate is utilized as a research tool in chemical studies. Its interactions with other substances and its properties can provide insights into the behavior of similar compounds and contribute to the advancement of chemical knowledge.

Upstream product

• 75-52-5 nitromethane 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 41661-47-6 piperidin-4-one 

Downstream Products

• 1160247-07-3 tert-butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate 
• 930785-40-3 1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylic acid tert-butyl ester 
• 392331-66-7 4-aminomethyl-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

SSTR5 ANTAGONISTS

This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Method for taking DAST reagent as removing reagent to synthetize conjugated nitroolefin substituted series derivative

The invention discloses a preparation method of taking a DAST reagent as a removing reagent to synthesize a conjugated nitroolefin substituted series derivative. The preparation method comprises the following steps that a carbonyl compound (compound II) i

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of BAF complex related disorders.

COMPOUNDS AND METHODS FOR TREATING SYNOVIAL SARCOMAS

The present invention includes compound and methods that are useful in treating certain cancers, such as synovial sarcomas.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7- diamine compounds (referred to herein as "PPDA compounds") that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES

Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS

The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds